NEWS
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
Optinose (NASDAQ:OPTN) announced the peer-reviewed publication of a paper in the International Forum of Allergy & Rhinology, highlighting the benefits of XHANCE in chronic rhinosinusitis (CRS) patients. The study, based on two 24-week randomized trials (ReOpen1 and ReOpen2), evaluated XHANCE versus EDS-placebo in CRS patients with and without prior sinus surgery.
Key findings include:
XHANCE improved symptoms, sinus opacification, and quality of life in both groups
Previous surgery is not required for CRS patients to benefit from XHANCE
XHANCE can be helpful for patients even after surgery
The Exhalation Delivery System™ with fluticasone (EDS-FLU; XHANCE) creates unique biomechanics that enable deposition of corticosteroid into sinuses and sinus drainage pathways, proving effective for treating chronic sinusitis without nasal polyps.
Key findings include:
XHANCE improved symptoms, sinus opacification, and quality of life in both groups
Previous surgery is not required for CRS patients to benefit from XHANCE
XHANCE can be helpful for patients even after surgery
The Exhalation Delivery System™ with fluticasone (EDS-FLU; XHANCE) creates unique biomechanics that enable deposition of corticosteroid into sinuses and sinus drainage pathways, proving effective for treating chronic sinusitis without nasal polyps.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1822Followers
98Following
15KVisitors
Follow